Clinical Trial

Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer

Study acronym: Neo-D2plus
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 23, 2019 (before its estimated November 1, 2023 completion). Its status may not reflect the trial's current state.
Summary
In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.
Trial Details
NCT Number NCT03961373
Lead Sponsor University of Siena
Conditions Locally Advanced Gastric Cancer
Enrollment 539 participants
Start Date 2018-11-05
Primary Completion 2023-11-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2019-05-23